We maintain Buy rating on Ashok Leyland Ltd by Mr. Bharat Gianani, Sr. Research Analyst - Automobile - Angel Broking Pvt Ltd

Below is the view on Ashok Leyland Ltd (ALL) 3QFY2016 Results by Mr. Bharat Gianani (Sr. Research Analyst - Automobile, Angel Broking Pvt Ltd)

“Ashok Leyland Ltd (ALL) 3QFY2016 results were in line with our estimates. Revenues grew 22% YoY to INR 4,085 cr driven largely by 23% YoY growth in the volumes. MHCV segment (constituting 80% of volumes) grew strongl

We maintain our Buy rating on Coal India Ltd by Mr. Rahul Dholam, Sr. Research Analyst- Metals & Mining - Angel Broking Pvt Ltd

Below is the view on Coal India Ltd (CIL) 3QFY2016 Results by Mr. Rahul Dholam (Sr. Research Analyst- Metals & Mining, Angel Broking Pvt Ltd)

Coal India (CIL) 3QFY2016 Results: EBITDA and Net profit ahead of estimates
 
“Coal India reported revenue in line with our expectations at INR 18,972cr (vs. our expecta

We maintain our Neutral view on Bank of India Ltd by Mr. Vaibhav Agrawal, VP Research- Banking - Angel Broking Pvt Ltd

Below is the view on Bank of India Ltd 3QFY2016 Results by Mr. Vaibhav Agrawal (VP Research- Banking, Angel Broking Pvt Ltd)

“Bank of India reported disappointing set of numbers with a net loss of INR 1,505cr for the quarter. Asset quality deteriorated further with Gross NPA ratio at 9.18% as against 7.55% QoQ while the Net NPA ratio came at 5.25% as against

Experts react as retail inflation hits 17-month high in January

MUMBAI  - India's annual consumer price inflation edged up to a 17-month high of 5.69 percent in January, driven up by higher food costs, government data showed on Friday.

Meanwhile, separate data showed India's industrial output contracted an annual 1.3 percent in December.

 

COMMENTARY

Yellen's dilemma: A downturn with no easy response

By Howard Schneider and Ann Saphir

WASHINGTON - The U.S. Federal Reserve's carefully scripted decision to raise interest rates last December, and begin a return to "normal" policy, may now become a nightmare for the central bank if an economic downturn forces a return to unconventional methods.

Fed chair Janet Yellen told lawma

What's behind the global stock market selloff?

By David Randall and David Gaffen

NEW YORK - Global stock markets are on their shakiest footing in years.

Investors are fleeing stocks and running to safe-havens like bonds and gold, driven by concerns about economic growth and the effectiveness of central banks' policies.

At the same time, tumbling energy prices are upe

We maintain our Neutral rating on IL&FS Transportation Network Ltd by Mr. Santosh Yellapu, Sr. Research Analyst - Infrastructure, Angel Broking Pvt Ltd

Below is the view on IL&FS Transportation Network Ltd (ITNL) 3QFY2016 Results by Mr. Santosh Yellapu (Sr. Research Analyst - Infrastructure, Angel Broking Pvt Ltd)

Higher other income drives ITNL‘s 3QFY2016 PAT
 
“For 3QFY2016, IL&FS Transportation Network (ITNL) reported top-line of INR 1,883cr, bel

We maintain our Neutral view on Union Bank of India Ltd by Mr. Vaibhav Agrawal, VP Research- Banking - Angel Broking Pvt Ltd

Below is the view on Union Bank of India Ltd 3QFY2016 Results by Mr. Vaibhav Agrawal (VP Research- Banking, Angel Broking Pvt Ltd)

“Union Bank of India reported 74% decline in PAT. Provisions rose 45.3% YoY to INR 1,237cr which included provisions on account of an intense asset quality review conducted by the Reserve Bank of India (RBI). This led to the shar

We continue to maintain our positive view on Voltas Ltd by Mr. Santosh Yellapu, Sr. Research Analyst - Infrastructure - Angel Broking Pvt Ltd

Below is the view on Voltas Ltd 3QFY2016 Results by Mr. Santosh Yellapu (Sr. Research Analyst - Infrastructure, Angel Broking Pvt Ltd)

3Q revenues better than expected, losses at EMP segment lead to disappointment at PAT level
 
“Voltas reported mix set of numbers, with better than expected top-line numbers and di

We have an Accumulate Rating on State Bank of India Ltd Mr. Vaibhav Agrawal, VP Research- Banking - Angel Broking Pvt Ltd

Below is the view on State Bank of India Ltd 3QFY2016 Results by Mr. Vaibhav Agrawal (VP Research- Banking, Angel Broking Pvt Ltd)

“SBI’s Q3FY16 reported PAT of INR 1,115 cr, in line with our expectations. Though this is a decline of 61.7% YoY and 71.2% QoQ, given the cleaning up exercise the bank is taking up towards NPAs and taking higher provision t

We maintain Neutral rating on NCC Ltd by Mr. Santosh Yellapu, Sr. Research Analyst - Infrastructure - Angel Broking Pvt Ltd

Below is the view on NCC Ltd 3QFY2016 Results by Mr. Santosh Yellapu (Sr. Research Analyst - Infrastructure, Angel Broking Pvt Ltd)

Reports better operating performance

“Despite miss on the 3QFY2016 revenues, NCC impressed us with YoY operating margin expansion. NCC reported top-line of INR 2,053cr, below our estimate of IN

We are Neutral on GlaxoSmithKline Pharmaceuticals Ltd by Ms. Sarabjit Kour Nangra, VP Research - Pharma - Angel Broking Pvt Ltd

Below is the view on GlaxoSmithKline Pharmaceuticals Ltd 3QFY2016 Results by Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking Pvt Ltd)

GlaxoSmithKline Pharmaceuticals (CMP:  INR 3,292/ TP: / Upside :)
 
“GlaxoSmithKline Pharmaceuticals, posted results below expectations. For 3QFY2016, the company

We advise Buy NBCC Ltd by Mr. Santosh Yellapu, Sr. Research Analyst - Infrastructure - Angel Broking Pvt Ltd

Below is the view on NBCC Ltd 3QFY2016 Results by Mr. Santosh Yellapu (Sr. Research Analyst - Infrastructure, Angel Broking Pvt Ltd)

Lower Other Income restricts PAT; Advise BUY post correction in the stock price
“NBCC reported 28.8% YoY increase in its 3QFY2016 top-line to INR 1,421cr, slightly below our expectation of INR 1,429cr. PMC & Real Es

We maintain our Buy rating on Aurobindo Pharma Ltd by Ms. Sarabjit Kour Nangra, VP Research - Pharma - Angel Broking Pvt Ltd

Below is the view on Aurobindo Pharma Ltd 3QFY2016 Results by Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking Pvt Ltd)

“The company disappointed on the revenue front which came in below expectations growing by 9.2% YoY to INR 3,432cr. This was against our expectations of INR 3,800cr. The key markets like USA (INR 1571cr) posted a YoY growth of

We maintain our Buy rating on Dr. Reddy's Laboratories Ltd by Ms. Sarabjit Kour Nangra, VP Research - Pharma - Angel Broking Pvt Ltd

Below is the view on Dr. Reddy's Laboratories Ltd 3QFY2016 Results by Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking Pvt Ltd)

“Dr Reddys Labs, posted results below expectations both on top and bottom-line. For 3QFY2016, the company posted sales of INR 3968cr V/s INR 4420cr expected and INR 3843cr in 3QFY2015, a YoY growth of 3.0%. The lowe

We maintain our Neutral view on Punjab National Bank Ltd by Mr. Vaibhav Agrawal, VP Research- Banking - Angel Broking Pvt Ltd

Below is the view on Punjab National Bank Ltd 3QFY2016 Results by Mr. Vaibhav Agrawal (VP Research- Banking, Angel Broking Pvt Ltd)

“PNB has come out with a very disappointing set of results for the quarter. Though results were expected to be bad however, the quantum of rise in Gross NPAs has surprised us. The Gross NPAs has gone up by 37.7% QoQ and now stan

We maintain our positive view PNC Infratech Ltd by Mr. Santosh Yellapu Sr. Research Analyst - Infrastructure - Angel Broking Pvt Ltd

Below is the view on PNC Infratech Ltd 3QFY2016 Results by Mr. Santosh Yellapu (Sr. Research Analyst - Infrastructure, Angel Broking Pvt Ltd)

PNC Infratech reports strong 3QFY2016 numbers
 
“PNC Infratech (PNC) reported strong set of numbers 3QFY2016 numbers. The performance was mainly driven by strong execution o

We maintain our Buy rating Ipca Laboratories Ltd by Ms. Sarabjit Kour Nangra, VP Research - Pharma - Angel Broking Pvt Ltd

Below is the view on Ipca Laboratories Ltd 3QFY2016 Results by Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking Pvt Ltd)

“IPCA Labs posted results lower than expected on all fronts. For 3QFY2016, the company posted sales of INR 674cr V/s INR 750cr expected; a YoY de-growth of 10.0% mainly impacted on back of exports, while domestic formulations

Expert views: India's economy grows 7.3 pct in October-December quarter

MUMBAI  - India said its economy grew 7.3 percent in the October-December quarter from a year earlier, in line with expectations, and forecast that gross domestic product would expand an annualised 7.6 percent in the fiscal year ending in March.

The latest full-year estimate compares with a revised 7.2 percent growth a year earlier.

&nb

We maintain our Accumulate rating On Cadila Healthcare Ltd by Ms. Sarabjit Kour Nangra, VP Research - Pharma - Angel Broking Pvt Ltd

Below is the view on Cadila Healthcare Ltd 3QFY2016 Results by Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking Pvt Ltd)

Cadila Healthcare (CMP: INR 312 / TP: INR 352/ Upside: 12.8% )
 
“Cadila Healthcare posted robust results during the quarter, on the net profit front, while the sales came in lower.

We are Neutral on Lupin Ltd by Ms. Sarabjit Kour Nangra, VP Research - Pharma - Angel Broking Pvt Ltd

Below is the view on Lupin Ltd 3QFY2016 Results by Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking Pvt Ltd)

“Lupin, posted results more or less in line with expectation barring the other income, which aided the net profit come in higher than expectations. For 3QFY2016, the company posted sales of INR 3358cr V/s INR 3400cr expected a YoY growth

We currently have Accumulate rating on Eicher Motors Ltd by Mr. Bharat Gianani, Sr. Research Analyst - Angel Broking Pvt Ltd

Below is the view on Eicher Motors 4QFY2016 Results by Mr. Bharat Gianani (Sr. Research Analyst - Automobile, Angel Broking Pvt Ltd)

“Eicher Motors 4QFY2016 consolidated results were in line with our estimates. Consolidated Revenues grew 45% YoY to INR 3,316 cr coming in line with our expectations. 2W business (Royal Enfield) topline grew strongly 55% YoY to